Menu
Search
|

Menu

Close
X

Dova Pharmaceuticals Inc DOVA.OQ (NASDAQ Stock Exchange Global Market)

24.33 USD
-0.04 (-0.16%)
As of Jul 20
chart
Previous Close 24.37
Open 24.39
Volume 63,750
3m Avg Volume 92,149
Today’s High 24.59
Today’s Low 24.14
52 Week High 35.52
52 Week Low 16.98
Shares Outstanding (mil) 25.65
Market Capitalization (mil) 714.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.518
FY17
-1.190
FY16
-1.205
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Paul Manning
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Alex Sapir
President, Chief Executive Officer, Director, Since 2017
Salary: $400,077.00
Bonus: $20,000.00
Mark Hahn
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Kevin Laliberte
Senior Vice President - Product Development, Since 2017
Salary: --
Bonus: --
Lee Allen
Chief Medical Officer, Since 2017
Salary: $285,221.00
Bonus: $20,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2530 Meridian Pkwy Ste 300
DURHAM   NC   27713-5273

Phone: +1919.8064487
Site: dova.com/

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Company’s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

SPONSORED STORIES